Research Overview of Mixtard 30 Penfill
Mixtard 30 Penfill is a biphasic insulin preparation formulated by Novo Nordisk for laboratory glucose metabolism studies. This research compound contains a standardised mixture of 30% soluble human insulin and 70% isophane human insulin suspension, providing researchers with a dual-phase insulin model for investigating glucose homeostasis mechanisms. The pharmaceutical-grade formulation allows scientists to examine both rapid and intermediate-acting insulin kinetics in controlled laboratory environments. Researchers at Stroid UK Shop utilise this preparation for comprehensive metabolic pathway investigations.
Laboratory Applications and Research Potential
Scientists investigate Mixtard 30 Penfill in glucose tolerance studies, examining how biphasic insulin formulations affect cellular glucose uptake mechanisms. The compound serves as a valuable reference standard for researchers studying insulin receptor binding kinetics and downstream signalling cascades. Laboratory investigations focus on the dual-phase pharmacokinetic profile, where the soluble component provides immediate glucose regulation while the isophane suspension delivers sustained metabolic effects. Studies examine the crystalline structure of insulin zinc suspensions and their impact on absorption rates in tissue models. Researchers exploring insulin research compounds often utilise this preparation alongside other metabolic modulators. The cartridge delivery system enables precise dosing protocols essential for reproducible experimental conditions. Comparative analyses investigate how biphasic formulations differ from single-phase insulin preparations in cellular assays. Scientists also examine the role of protamine sulfate in creating the intermediate-acting insulin component. Research applications extend to studying insulin stability under various storage conditions and pH environments. Metabolic researchers frequently compare this compound with other glucose-regulating substances available from suppliers of SARMs and peptides to understand comprehensive metabolic pathway interactions.
Technical Specifications and Research Parameters
| Parameter | Specification |
|---|---|
| Insulin Concentration | 100 IU/mL |
| Composition | 30% soluble insulin, 70% isophane insulin |
| Volume per Cartridge | 3.0 mL |
| pH Range | 7.0-7.8 |
| Manufacturer | Novo Nordisk |
| Formulation Type | Biphasic suspension |
| Storage Temperature | 2-8°C (unopened) |
| Research Applications | Glucose metabolism studies |
Compliance and Research-Only Usage
Mixtard 30 Penfill is supplied exclusively for in-vitro laboratory research purposes. This pharmaceutical preparation is intended for qualified researchers investigating glucose metabolism, insulin receptor mechanisms, and related metabolic pathways in controlled laboratory environments. The compound is not intended for human consumption, clinical administration, or therapeutic applications. Researchers must maintain appropriate storage conditions and follow institutional protocols for handling pharmaceutical-grade research materials. All investigations must comply with relevant research guidelines and safety protocols established by accredited laboratory facilities.
